You may also need to upgrade your Flash Player.
You can upgrade your flash player by Clicking Here »
Options in Medicare coverage can be more complicated than IG therapy, but these guidelines for individuals turning 65 can help to ensure a smooth transition.
HSCT (also known as bone marrow transplant [BMT]) is used to treat certain forms of Primary Immunodeficiency (PI), and it is becoming much more successful due to better tissue typing and matching of donors, less toxic chemotherapy, better virus detection and treatment, improved supportive care and graft-versus-host disease (GVHD) prophylaxis.
Getting reimbursed for immune globulin (IG) can be challenging and frustrating. What is required when submitting a claim may vary, but accuracy in submission is imperative.
While patients are at risk for long-term complications due to primary immunodeficiencies, these can be mitigated through early diagnosis and treatment.
This autoimmune disease is difficult to diagnose due to its rarity and many variants, but once it is diagnosed, there are treatment options.
The only way to effectively treat neuropathies is to identify which of the many different diseases is the underlying cause and then make the proper diagnosis.
Studies that examine the relationships between therapeutic doses of IG, trough IgG levels and infection rates shed new light on how IG replacement therapy should be prescribed for individuals.
Early referrals for workup can dramatically reduce hospitalizations, permanent disability and high cost of care.
When choosing a site of care for immune globulin therapy, each patient’s unique situation must be considered.
Treatment for this type of hemophilia must be individualized for each patient, but the prognosis is often good.
How much IG to prescribe differs for each individual based on a variety of clinical and non-clinical factors, as well as physician discretion.
Immune globulin (IG) is used to treat a wide range of disorders. While the most common use of IG therapy is in treating primary immune deficiencies, its efficacy in numerous other disorders is well-documented.
Knowing what side effects, from mild to serious, to expect during and after immune globulin infusions can prepare patients and their caregivers for treatment changes to mitigate their impact.
With the FDA approval of SCIG therapy in 2006, many patients now have the choice between SCIG and IVIG infusions. Understanding the differences between the two treatment modalities will help healthcare providers recommend the right one for their patients.
During the past three decades, IVIG has proven an effective treatment for a wide range of autoimmune diseases, and it is now believed that IVIG may have clinical uses for a broader range of medical conditions.